Thus, TGF-β1 is considered as a potential biomarker for renal fibrosis and inhibiting TGF-β1/Smad2/3 pathway may represent an effective therapy for DN associated with progressive real fibrosis [9]. The gene discussed is TGFB1; the disease is liver dysplastic nodule.